Effect of cholecystectomy on liver fat and fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) patients. Prospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511511917109

Enrollment

210

Registered

2025-11-03

Start date

2021-03-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

MAFLD

Cholecystectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 18 to 75 who underwent cholecystectomy for symptomatic gallbladder stones and exhibited MASLD in intraoperative liver biopsy, or individuals with liver stiffness of 7.2 kPa or greater scheduled for percutaneous liver biopsy 24 to 48 hours after FibroScan®, were included in this study.

Exclusion criteria

Exclusion criteria: Pregnant women, patients with ascites, individuals who have refused LB surgery, those with complications from diabetes mellitus, excessive alcohol consumers (exceeding 30 grams per day for men and 20 grams per day for women), individuals with hepatitis (viral B/C, autoimmune, or cholestatic), patients with specimens measuring less than 10 mm and fewer than 6 portal areas (PA), individuals with advanced cardiovascular disease, malignant neoplasia, those on steatogenic medications, or those displaying vesicular neoplasia upon histological examination

Design outcomes

Primary

Measure	Time frame
Effect of cholecystectomy on liver fat and fibrosis in Metabolic dysfunction-associated steatotic liver disease (MASLD) patients	—

Secondary

Measure	Time frame
risk factors of MAFLD	—

Countries

Algeria

Contacts

Public ContactKhellaf Amalou

Hospital

amalou_kh@yahoo.fr00213661615850

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026